沙格列汀在早期糖尿病肾病患者非依赖降脂中的肾脏保护作用研究

Study on the Renal Protective Effect of Saxagliptin in Patients with Early Diabetic Nephropathy

目的探讨沙格列汀在早期糖尿病肾病(DN)患者非依赖降脂中的肾脏保护作用。方法选取2019年1月—2020年12月该院收治的80例早期DN患者,按随机数表法分两组,各40例。对照组给予早期DN常规疗法治疗,观察组在对照组基础上给予沙格列汀治疗,比较两组治疗前、治疗4周及16周时血脂指标,肾功能指标、炎症指标及不良反应发生情况。结果治疗4周、16周时,观察组TC、TG及LDL-C水平均低于对照组,而HDL-C水平高于对照组,差异有统计学意义(P<0.05);治疗4周、16周时,观察组Scr、BUN及24 h尿蛋白定量均低于对照组,差异有统计学意义(P<0.05);治疗4周、16周时,观察组CRP水平(10.28±1.37)、(7.10±1.25)mg/L低于对照组,差异有统计学意义(t=5.569、4.592,P<0.05)。两组不良反应总发生率相比,差异无统计学意义(P>0.05)。结论对早期DN患者于常规治疗基础上增加沙格列汀治疗,不但可有效调节患者机体血脂状态,而且还可通过改善机体微炎症状态等非依赖降脂作用来有效保护患者肾脏功能。

Objective To investigate the renal protective effect of saxagliptin in patients with early diabetic nephropathy(DN)in non-dependent lipid-lowering.Methods A total of 80 patients with early DN admitted to the hospital from January 2019 to December 2020 were selected and divided into two groups according to the random number table method,with 40 cases in each group.The control group was treated with early DN conventional therapy,and the observation group was treated with saxagliptin on the basis of the control group.The blood lipid indexes,renal function indexes,inflammation indexes and adverse reactions were compared between the two groups before treatment,4 weeks and 16 weeks after treatment.Results At 4 and 16 weeks of treatment,the levels of TC,TG and LDL-C in the observation group were lower than those in the control group,while the levels of HDL-C were higher than those in the control group.The difference was statistically significant(P<0.05);At 16 weeks,the observation group's Scr,BUN and 24h urine protein quantitative were lower than those of the control group,the difference was statistically significant(P<0.05);at 4 weeks and 16 weeks of treatment,the observation group's CRP levels(10.28±1.37)mg/L,(7.10±1.25)mg/L was lower than the control group,the difference was statistically significant(t=5.569,4.592,P<0.05).There was no Statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The addition of saxagliptin therapy to early DN patients on the basis of conventional treatment can not only effectively regulate the blood lipid status of the patient,but also can effectively protect the kidney function of the patient by improving the non-dependent lipid-lowering effects such as improving the micro-inflammatory state of the body.